Lakefront Biotherapeutics (LKFT) Receivables (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Receivables data on file, last reported at $25.4 million in Q1 2026.

• Receivables for Q1 2026 came in at $25.4 million, down 66.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.4 million (down 66.8% YoY), and the FY2025 annual result was $28.6 million, down 46.26% from the prior year.
• Receivables declined to $25.4 million in Q1 2026 per LKFT's latest filing, from $28.6 million in the prior quarter.
• Over five years, Receivables peaked at $103.0 million in Q1 2024 and troughed at $25.4 million in Q1 2026.
• A 5-year average of $59.4 million and a median of $53.0 million in 2025 frame the typical range for Receivables.
• The sharpest annual moves came in 2024 and 2026: Receivables jumped 131.6% in 2024, then tumbled 66.8% in 2026.
• A 5-year view of Receivables shows it stood at $49.3 million in 2022, then dropped by 26.54% to $36.2 million in 2023, then surged by 46.83% to $53.2 million in 2024, then plunged by 46.26% to $28.6 million in 2025, then declined by 10.9% to $25.4 million in 2026.
• Business Quant data shows LKFT's Receivables at $25.4 million in Q1 2026, $28.6 million in Q4 2025, and $53.0 million in Q3 2025.